Abstract 744P
Background
ACR-368 (prexasertib), a potent, selective CHK1/2 inhibitor, has shown durable single-agent activity at RP2D in patients (pts) with OvCa. ACR-368-OncoSignature (BM) is a predictive biomarker test derived from Acrivon Predictive Precision Proteomics (AP3) designed to predict benefit from ACR-368. It has been evaluated in 2 prospectively designed, blinded studies on pretreatment tumor biopsies from past trials demonstrating significant responder enrichment. Furthermore, it -identified EnCa as a new tumor type predicted sensitive to ACR-368 (Murshid et al, AACR-EORTC-NCI 2023) which is now tested in this trial.
Methods
BM was determined on a fresh biopsy in pts with platinum resistant OvCa or EnCa. BM-positive pts (Arm 1) received ACR-368 at RP2D (105 mg/m2) as monotherapy. BM-negative pts (Arm 2) received ACR-368 at RP2D with ultra-low dose of gemcitabine (ULDG; 10 mg/m2). Primary endpoint in Arm 1 was ORR by RECIST 1.1 in a Simon 2-Stage design. Primary endpoint in Arm 2 was safety and RP2D for ULDG, secondary was ORR.
Results
Of 26 efficacy-evaluable patients, all RECIST responses (2 OvCa, 3 EnCa) occurred in Arm 1. No RECIST responses were observed in Arm 2. This provides initial prospective validation of the ACR-368 OncoSignature showing segregation of RECIST responders in the OncoSignature-positive (50% cPR in 10 pts) versus OncoSignature-negative (0% PR in 16 pts) arm (p-value=0.0038). Table: 744P
Data cut-off April 1, 2024 | OncoSignature Positive (N=10) | OncoSignature Negative (N=16) | ||
Ovarian | Endometrial | Ovarian | Endometrial | |
Confirmed PR | 2 | 3* | 0 | 0 |
SD | 2 | 1 | 6 | 2 |
PD | 1 | 1 | 5 | 3 |
Total | 5 | 5 | 11 | 5 |
ORR (%) (95% CI) | 40ˆ (12%, 77%) | 60# (23%, 88%) | 0ˆ | 0# |
ORR (%) GYN Total (95% CI) | 50 (23%, 76%) | 0 |
NOTES: * 1 PR (EnCa) confirmed 1 day after data cut-off. ˆ Unenriched ORR in pts with OvCa (N=16) = 12% consistent with past multi-center trial (12.5%; Konstantinopoulos et al, Gyn Oncol, 2022). # EnCa is a new tumor type predicted to be sensitive to ACR-368 by AP3-based indication finding not previously evaluated
Adverse events (of 3/8/24; N=21 Arm 1, N= 33 Arm 2) were predominantly transient, mechanism-based, consistent with prior studies (Gr 3/4 anemia, thrombocytopenia, neutropenia and febrile neutropenia observed in Arm1/Arm2 pts were (%/%): 19/15, 10/9, 5/15, and 10/15, respectively).
Conclusions
Initial clinical data from this prospective trial supports the clinical utility of the ACR-368-OncoSignature as a pts selection tool to identify OvCa and EnCa pts sensitive to ACR-368.
Clinical trial identification
NCT05548296.
Editorial acknowledgement
Legal entity responsible for the study
Acrivon Therapeutics.
Funding
Acrivon Therapeutics.
Disclosure
D. Matei: Financial Interests, Personal, Advisory Board: GSK, Eisai; Financial Interests, Personal, Other, Consultant: CVS Health; Financial Interests, Personal, Other, Mentor fee: GOG Foundation; Financial Interests, Institutional, Local PI: Acrivon, Eisai, Shattuck Labs, Moderna; Financial Interests, Institutional, Coordinating PI: Merck. L. Brubaker: Financial Interests, Personal, Advisory Board, Isolated AdBoard participation in October 2022 and May 2024: AstraZeneca. B. Rimmel: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, ImmunoGen, Merck. R.N. Eskander: Financial Interests, Personal, Advisory Board: AstraZeneca, Eisai, MSD, Clovis Oncology, Myraid, CARIS life sciences, PMV Pharma, Daiichi Sankyo, Regeneron, ImmunoGen, Seagen, AbbVie, Nuvectis Pharma, Faeth Therapeutics, Genentech/Roche; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Institutional, Funding: CanarioBio, Immunognen, Alkermes, Acrivon, ProfoundBio; Non-Financial Interests, Principal Investigator: Gilead, NRG Oncology; Financial Interests, Advisory Role: GOG-Foundation, Clearity Foundation. C. Kyi: Financial Interests, Institutional, Advisory Board: Scenic Biotech; Financial Interests, Personal, Other, Honoraria for educational symposiums: Onclive, Total Health; Financial Interests, Institutional, Coordinating PI: Bristol Myers Squibb, Centessa Pharmaceuticals, Gritstone Bio, Incyte, Eisai, Merus; Financial Interests, Institutional, Steering Committee Member: Acrivon Therapeutics. L. Duska: Financial Interests, Personal, Advisory Board, Scientific advisory board: Aadi Bioscience; Financial Interests, Personal, Royalties, I write expert content for UpToDate: UpToDate; Financial Interests, Personal, Other, I serve on the Editorial Board: British Journal of Obstetrics and Gynecology; Financial Interests, Institutional, Research Grant, Merck has provided funding for investigator initiated trials to my institution: Merck; Non-Financial Interests, Advisory Role, Acted as an expert advisor for: Merck. F. Musa: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca; Financial Interests, Personal, Writing Engagement: Seagen; Financial Interests, Institutional, Local PI: GSK, Allarity Pharmaceuticals, Duality Bio, Aravive, Clovis; Non-Financial Interests, Member of Board of Directors: Society of Gynecologic Oncology. R.L. Coleman: Financial Interests, Personal, Advisory Board: AstraZeneca, Alkermes, ImmunoGen, roche/genentech, GSK, Genmab/Seagen, Epsilogen, Myriad Genetics, Panavance, Profoundbio; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Trial Chair: ImmunoGen; Financial Interests, Personal, Steering Committee Member: Merck, Roche-Genentech, Verastem, AstraZeneca, Gsk; Financial Interests, Personal, Coordinating PI: Karyopharm; Non-Financial Interests, Principal Investigator: abbvie, immunogen, Roche/Genentech, Merck, Genmab; Non-Financial Interests, Project Lead, MyLung Consortium: US Oncology Research. B.M. Slomovitz: Financial Interests, Personal, Advisory Board: AstraZeneca, Eisai, GSK, Genentech, Merck, ImmunoGen, Novocure, Aadi, Seagen, Incyte; Non-Financial Interests, Member of Board of Directors: GOG Foundation. E.C. Gamelin: Financial Interests, Personal, Full or part-time Employment: Acrivon. J. Cuillerot: Financial Interests, Personal, Full or part-time Employment: Acrivon Therapeutics; Financial Interests, Personal, Stocks/Shares, Stock options: Acrivon Therapeutics; Financial Interests, Personal, Stocks/Shares: BMS, DragonflyTx, SkyHawks. M.M. Phadnis: Financial Interests, Personal, Full or part-time Employment, Senior Vice President, Clinical Operations: Acrivon Therapeutics. B. Guercio: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Institutional, Local PI: Genentech, Acrivon; Financial Interests, Institutional, Coordinating PI: Exelixis; Financial Interests, Institutional, Research Grant: Oncocyte; Financial Interests, Institutional, Funding: Bristol Myers Squibb; Non-Financial Interests, Other, Speaker and grant reviewer: Bladder Cancer Advocacy Network; Non-Financial Interests, Member: ASCO, AACR; Other, Invited speaker at conference - travel expenses paid for by Dava Oncology: Dava Oncology; Other, Dinner: Aveo Oncology, Natera, Seagen, Exelixis. P. Konstantinopoulos: Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, Alkermes, Kadmon, Bristol Myers Squibb, Artios, Schrodinger, Mersana, Novartis, ImmunoGen, Merck KGaA; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Bayer, Merck, Pfizer, GSK, Merck KGaA, Lilly, Bristol Myers Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
661P - Safety and activity of CY-101 in patients with advanced solid tumors: The phase I/IIa CICILIA trial
Presenter: Barend Sikkema
Session: Poster session 01
662P - A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Presenter: Yuping Sun
Session: Poster session 01
663P - First-in-human, phase I/II, monotherapy, dose-escalation study of mRNA-4359, an mRNA-encoded PD-L1/IDO1 antigen-specific therapy, in advanced/refractory solid tumors
Presenter: Muhammad Khattak
Session: Poster session 01
664P - Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)
Presenter: Maria Julia Lostes Bardaji
Session: Poster session 01
665P - Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Thomas Marron
Session: Poster session 01
Resources:
Abstract
666P - Final results of phase I/II study of NUC-7738 as monotherapy and in combination with pembrolizumab: Anti-tumor immune response in PD-1 inhibitor-resistant patients
Presenter: Sarah Blagden
Session: Poster session 01
667P - Phase I study to assess biodistribution of CB307, a trispecific Humabody targeting CD137, prostate-specific membrane antigen, and human serum albumin with 89Zr-CB307 PET
Presenter: Daan Geert Knapen
Session: Poster session 01
668P - First-in-human phase I dose escalation study of ALG.APV-527, a 5T4 tumor antigen-conditional 4-1BB bispecific antibody, in patients with advanced solid tumors, demonstrates positive safety, signals of biological activity and patients with lasting stable disease
Presenter: Thomas Marron
Session: Poster session 01
669P - CBX-12-101: Final results of a phase I study of CBX-12, a peptide drug conjugate (PDC) in patients (pts) with metastatic solid tumors
Presenter: Patricia Lorusso
Session: Poster session 01
670P - Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-Like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data
Presenter: Martin Wermke
Session: Poster session 01